Kutluay Nur Burcu, Bektay Muhammed Yunus, Sumbul-Sekerci Betul, Sekerci Abdusselam, Izzettin Fikret Vehbi
Clinical Pharmacy Department, Institute of Health Sciences, Bezmialem Vakif University, Istanbul, Turkey.
Clinical Pharmacy Department, Faculty of Pharmacy, Bezmialem University, Istanbul, Turkey.
BMC Health Serv Res. 2025 Jan 20;25(1):107. doi: 10.1186/s12913-025-12233-7.
Diabetes is a chronic disease with increasing prevalence. There is growing evidence pharmacist can contribute to clinical outcomes. This study aims to evaluate contribution of pharmacist to prediabetes and diabetes care.
A Prospective cohort study designed to evaluate the effects of pharmacist intervention on prediabetes (pDG) and type II diabetes mellitus (DMG) patients. The pharmacist conducted a detailed medication review and structured patient education during the first visit, followed by an evaluation of the interventions at the second visit (after 90 days). The effects were assessed by comparing fasting plasma glucose, HbA1c, the homeostasis model assessment-estimated insulin resistance (HOMA-IR), lipid profile, BMI, waist circumference, illness perception, and diabetes knowledge. Diabetes and preDiabetes knowledge was measured using the Diabetes and preDiabetes Knowledge Measurement Questionnaire (DKMQ and PKMQ), and illness perception with the Illness Perception Questionnaire-Revised (IPQ-R) The effect of pharmacist on diabetes care was assessed with a pre-post intervention comparison. The statistical significance was set at p < 0.05.
A total of 145 (79 diabetes and 66 prediabetes) patients were included. The mean age of pDG and DMG were 45.79 ± 1.40 and 49.24 ± 1.08 years respectively. A statistically significant improvement was observed in weight, waist circumference, blood glucose, cholesterol, HbA1c, and HOMA-IR levels when comparing pre- and post-pharmacist intervention over the 90-day interval (p < 0.05). Statistically difference was observed in DKMQ, PKMQ and IPQ-R scores among the pDG and DMG (p < 0.001).
Pharmaceutical care services provided to diabetes patients had positive effects on disease prognosis, knowledge levels and disease perceptions. Patients with HbA1c level higher than 9% had the greatest benefit from pharmacist interventions.
糖尿病是一种患病率不断上升的慢性疾病。越来越多的证据表明药剂师可以对临床结果做出贡献。本研究旨在评估药剂师对糖尿病前期和糖尿病护理的贡献。
一项前瞻性队列研究，旨在评估药剂师干预对糖尿病前期（pDG）和2型糖尿病（DMG）患者的影响。药剂师在首次就诊时进行了详细的用药审查和结构化的患者教育，随后在第二次就诊时（90天后）对干预措施进行评估。通过比较空腹血糖、糖化血红蛋白、稳态模型评估估计的胰岛素抵抗（HOMA-IR）、血脂谱、体重指数、腰围、疾病认知和糖尿病知识来评估效果。使用糖尿病和糖尿病前期知识测量问卷（DKMQ和PKMQ）测量糖尿病和糖尿病前期知识，使用修订后的疾病认知问卷（IPQ-R）测量疾病认知。通过干预前后的比较来评估药剂师对糖尿病护理的影响。统计学显著性设定为p < 0.05。
共纳入145例患者（79例糖尿病患者和66例糖尿病前期患者）。pDG和DMG的平均年龄分别为45.79±1.40岁和49.24±1.08岁。在90天的时间间隔内，比较药剂师干预前后，体重、腰围、血糖、胆固醇、糖化血红蛋白和HOMA-IR水平有统计学显著改善（p < 0.05）。在pDG和DMG之间，DKMQ、PKMQ和IPQ-R评分有统计学差异（p < 0.001）。
为糖尿病患者提供的药学服务对疾病预后、知识水平和疾病认知有积极影响。糖化血红蛋白水平高于9%的患者从药剂师干预中获益最大。
